These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 37965333)

  • 1. Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA sequencing and bulk RNA sequencing techniques.
    He D; Tang H; Yang X; Liu X; Zhang Y; Shi J
    Front Immunol; 2023; 14():1278496. PubMed ID: 37965333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of disulfidptosis-associated genes and characterization of immune cell infiltration in thyroid carcinoma.
    Song S; Zhou J; Zhang L; Sun Y; Zhang Q; Tan Y; Zhou X; Yu J
    Aging (Albany NY); 2024 Jun; 16(11):9753-9783. PubMed ID: 38836761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
    Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
    Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-seq and bulk RNA-seq data analysis of cancer-related fibroblasts (CAF) in LUAD to construct a CAF-based risk signature.
    Si Y; Zhao Z; Meng X; Zhao K
    Sci Rep; 2024 Oct; 14(1):23243. PubMed ID: 39369095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals immune suppression subtypes and establishes a novel signature for determining the prognosis in lung adenocarcinoma.
    Mao S; Wang Y; Chao N; Zeng L; Zhang L
    Cell Oncol (Dordr); 2024 Oct; 47(5):1697-1713. PubMed ID: 38616208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel signature of the ligand and receptor genes associated with disulfidoptosis for prediction of prognosis, immunologic therapy responses in hepatocellular carcinoma.
    Fu C; Cheng C; Zhang Y
    Heliyon; 2023 Sep; 9(9):e19502. PubMed ID: 37662746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
    Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
    Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis Reveals Disulfidoptosis-Associated Genes as Promising Immunotherapeutic Targets: Insights Gained from Bulk Omics and Single-Cell Sequencing Validation.
    Xu B; Li M; Weng N; Zhou C; Chen Y; Wei J; Fu L
    Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative analysis of single-cell and bulk RNA-sequencing data revealed disulfidptosis genes-based molecular subtypes and a prognostic signature in lung adenocarcinoma.
    Wang H; Zhu X; Zhao F; Guo P; Li J; Du J; Shan G; Li Y; Li J
    Aging (Albany NY); 2024 Feb; 16(3):2753-2773. PubMed ID: 38319721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
    Sui P; Liu X; Zhong C; Sha Z
    Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma.
    Zhang P; Pei S; Gong Z; Feng Y; Zhang X; Yang F; Wang W
    Front Immunol; 2023; 14():1115272. PubMed ID: 36776843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
    Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.
    He J; Zhang W; Li F; Yu Y
    Math Biosci Eng; 2021 Jul; 18(5):5959-5977. PubMed ID: 34517518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative Analysis of Single-Cell and Bulk RNA Sequencing Reveals Prognostic Characteristics of Macrophage Polarization-Related Genes in Lung Adenocarcinoma.
    Mi K; Zeng L; Chen Y; Yang S
    Int J Gen Med; 2023; 16():5031-5050. PubMed ID: 37942473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revealing a cancer-associated fibroblast-based risk signature for pancreatic adenocarcinoma through single-cell and bulk RNA-seq analysis.
    Ma J; Chen Z; Hou L
    Aging (Albany NY); 2024 Sep; 16(18):12525-12542. PubMed ID: 39332020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
    Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
    Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the potential of senescence-related genes in guiding clinical therapy of lung adenocarcinoma patients.
    Liu C; Wei X
    Funct Integr Genomics; 2023 May; 23(2):188. PubMed ID: 37246190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
    Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
    Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.